Trial Profile
To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 01 Feb 2020 Planned End Date changed from 25 Apr 2019 to 17 Sep 2020.
- 01 Feb 2020 Status changed to active, no longer recruiting.
- 25 Apr 2017 New trial record